Retargeting R-type pyocins to generate novel bactericidal protein complexes

Applied and Environmental Microbiology

Volumn 74, Issue 12, 2008, Pages 3868-3876

  Williams, Steven R ^a   Gebhart, Dana ^a   Martin, David W ^a   Scholl, Dean ^a  

^a AvidBiotics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOLOGY; BACTERIOPHAGES; DRUG THERAPY; ESCHERICHIA COLI; FIBER OPTICS; HEALTH; ROUGH SET THEORY; STRAIN;

(060.2410) FIBERS; AMERICAN SOCIETY; BACTERIAL GENUS; BACTERIAL MEMBRANES; BACTERIOCINS; CLINICAL UTILITY; COLLATERAL DAMAGE; MULTIDRUG RESISTANCE (MDR); P. AERUGINOSA; PROTEIN COMPLEXES; PSEUDOMONAS AERUGINOSA (APRIN); SPECTRA (CO); TAIL STRUCTURES; YERSINIA PESTIS;

FIBERS;

BACTERIOCIN; PYOCIN;

ANTIBIOTICS; BACTERIUM; DRUG RESISTANCE; GENETIC ENGINEERING; PESTICIDE; PROTEIN;

ARTICLE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ESCHERICHIA COLI; INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ENGINEERING; PROTEIN TARGETING; PSEUDOMONAS AERUGINOSA; YERSINIA PESTIS;

ANTI-BACTERIAL AGENTS; ARTIFICIAL GENE FUSION; BACTERIOPHAGES; COLIPHAGES; DNA, BACTERIAL; ESCHERICHIA COLI; MOLECULAR SEQUENCE DATA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGES; PYOCINS; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA; YERSINIA PESTIS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; YERSINIA PESTIS;

EID: 45749147914     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/AEM.00141-08     Document Type: Article

References (46)

1. Beaber, J. W., B. Hochhut, and M. K. Waldor. 2004. SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature 427:72-74.
2. Birmingham, V. A., and P. A. Pattee. 1981. Genetic transformation in Staphylococcus aureus: isolation and characterization of a competence-conferring factor from bacteriophage 80α lysates. J. Bacteriol. 148:301-307.
3. Blackwell, C. C., and J. A. Law. 1981. Typing of non-serogroupable Neisseria meningitidis by means of sensitivity to R-type pyocins of Pseudomonas aeruginosa. J. Infect. 3:370-378.
4. Blackwell, C. C., F. P. Winstanley, and W. A. Telfer-Brunton. 1982. Sensitivity of thermophilic campylobacters to R-type pyocines of Pseudomonas aeruginosa. J. Med. Microbiol. 15:247-251.
5. Campagnari, A. A., R. Karalus, M. Apicella, W. Melaugh, A. J. Lesse, and B. W. Gibson. 1994. Use of pyocin to select a Haemophilus ducreyi variant defective in lipooligosaccharide biosynthesis. Infect. Immun. 62:2379-2386.
6. Chenna, R., H. Sugawara, T. Koike, R. Lopez, T. J. Gibson, D. G. Higgins, and J. D. Thompson. 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31:3497-3500.
7. Chuanchuen, R., C. T. Narasaki, and H. P. Schweizer. 2002. Benchtop and microcentrifuge preparation of Pseudomonas aeruginosa competent cells. BioTechniques 33:760-763.
8. Clamp, M., J. Cuff, S. M. Searle, and G. J. Barton. 2004. The Jalview Java alignment editor. Bioinformatics 20:426-427.
9. Coetzee, H. L., H. C. De Klerk, J. N. Coetzee, and J. A. Smit. 1968. Bacteriophage-tail-like particles associated with intra-species killing of Proteus vulgaris. J. Gen. Virol. 2:29-36.
10. Filiatrault, M. J., R. S. Munson, Jr., and A. A. Campagnari. 2001. Genetic analysis of a pyocin-resistant lipooligosaccharide (LOS) mutant of Haemophilus ducreyi: restoration of full-length LOS restores pyocin sensitivity. J. Bacteriol. 183:5756-5761.
11. Garcia, E., P. Chain, J. M. Elliott, A. G. Bobrov, V. L. Motin, O. Kirillina, V. Lao, R. Calendar, and A. A. Filippov. 2007. Molecular characterization of L-413c, a P2-related plague diagnostic bacteriophage. Virology 372:85-96.
12. Haas, H., T. Sacks, and N. Saltz. 1974. Protective effect of pyocin against lethal Pseudomonas aeruginosa infections in mice. J. Infect. Dis. 129:470-472.
13. Hagens, S., A. Habel, U. von Ahsen, A. von Gabain, and U. Bläsi. 2004. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 48:3817-3822.
14. Haggård-Ljungquist, E., C. Halling, and R. Calendar. 1992. DNA sequences of the tail fiber genes of bacteriophage P2: evidence for horizontal transfer of tail fiber genes among unrelated bacteriophages. J. Bacteriol. 174:1462-1477.
15. Hoang, T. T., R. R. Karkhoff-Schwelzer, A. J. Kutchma, and H. P. Schwelzer. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212:77-86.
16. Hurley, J. C. 1995. Antibiotic-induced release of endotoxin. A therapeutic paradox. Drug Safety 12:183-195.
17. Ikeda, K., and F. Egami. 1968. Receptor substance for pyocin R. I. Partial purification and chemical properties. J. Biochem. (Tokyo) 65:603-609.
18. Infectious Diseases Society of America. 2004. Bad bugs, no drugs. Infectious Diseases Society of America, Arlington, VA.
19. Ito, S., M. Kageyama, and F. Egami. 1970. Isolation and characterization of pyocins from several strains of Pseudomonas aeruginosa. J. Gen. Appl. Microbiol. 16:205-214.
20. Jabrane, A., A. Sabri, P. Compère, P. Jacques, I. Vandenberghe, J. Van Beeumen, and P. Thenart. 2002. Characterization of serracin P, a phage-tail-like bacteriocin, and its activity against Erwinia amylovora, the fire blight pathogen. Appl. Environ. Microbiol. 68:5704-5710.
21. Jiang, X., H. Yang, B. Dettman, and M. P. Doyle. 2006. Analysis of fecal microbial flora for antibiotic resistance in ceftiofur-treated calves. Foodborne Pathog. Dis. 3:355-365.
22. Kageyama, M. 1975. Bacteriocins and bacteriophages in Pseudomonas aeruginosa, p. 291-305. In T. Mitsuhashi and H. Hashimoto (ed.), Microbial drug resistance. University of Tokyo Press, Tokyo, Japan.
23. Kageyama, M., K. Ikeda, and F. Egami. 1964. Studies of a pyocin. I. Physical and chemical properties. J. Biochem. 55:49-53.
24. Kageyama, M., K. Ikeda, and F. Egami. 1964. Studies of a pyocin. III. Biological properties of the pyocin. J. Biochem. 55:59-64.
25. Matsui, H., Y. Sano, H. Ishihara, and T. Shinomiya. 1993. Regulation of pyocin genes in Pseudomonas aeruginosa by positive (prtN) and negative (prtR) regulatory genes. J. Bacteriol. 175:1257-1263.
26. Merrikin, D. J., and C. S. Terry. 1972. Use of pyocin 78-C2 in the treatment of Pseudomonas aeruginosa infection in mice. Appl. Microbiol. 23:164-165.
27. Michel-Briand, Y., and C. Baysse. 2002 The pyocins of Pseudomonas aeruginosa. Biochimie 84:499-510.
28. Miller, C. P. 1951. New problems in the treatment of infectious diseases. Ann. Intern. Med. 35:763-770.
29. Morse, S. A., and M. A. Apicella. 1982. Isolation of a lipopolysaccharide mutant of Neisseria gonorrhoeae: an analysis of the antigenic and biological difference. J. Infect. Dis. 145:206-216.
30. Morse, S. A., B. V. Jones, and P. G. Lysko. 1980. Pyocin inhibition of Neisseria gonorrhoeae: mechanism of action. Antimicrob. Agents Chemother. 18:416-423.
31. Morse, S. A., P. Vaughan, D. Johnson, and B. H. Iglewski. 1976. Inhibition of Neisseria gonorrhoeae by a bacteriocin from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 10:354-362.
32. Nakayama, K., K. Takashima, H. Ishihara, T. Shinomiya, and M. Kageyama. 2000. The R-type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F-type is related to lambda phage. Mol. Microbiol. 38: 213-231.
33. Opar, A. 2007. Bad bugs need more drugs. Nat. Rev. Drug Discov. 6:943-944.
34. Sandlin, R. C., R. J. Danaher, and D. C. Stein. 1994. Genetic basis of pyocin resistance in Neisseria gonorrhoeae. J. Bacteriol. 176:6869-6876.
35. Scholl, D., and D. W. Martin. 2008. Antibacterial efficacy of R-type pyocin towards Pseudomonas aeruginosa in a murine peritonitis model. Antimicrob. Agents Chemother. 52:1647-1652.
36. Shinomiya, T. 1984. Phenotypic mixing of pyocin R2 and bacteriophage PS17 in Pseudomonas aeruginosa PAO. J. Virol. 49:310-314.
37. Shinomiya, T., and S. Ina. 1989. Genetic comparison of bacteriophage PS17 and Pseudomonas aeruginosa R-type pyocin. J. Bacteriol. 171:2287-2292.
38. Shinomiya, T., S. Shiga, and M. Kageyama. 1983. Genetic determinant of pyocin R2 in Pseudomonas aeruginosa PAO. I. Localization of the pyocin R2 gene cluster between the trpCD and trpE genes. Mol. Gen. Genet. 189:375-381.
39. Somerville, J. E., Jr., L. Cassiano, and R. P. Darveau. 1999. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun. 67:6583-6590.
40. Strauch, E., H. Kaspar, C. Schaudinn, P. Dersch, K. Madela, C. Gewinner, S. Hertwig, J. Wecke, and B. Appel. 2001. Characterization of enterocoliticin, a phage tail-like bacteriocin, and its effect on pathogenic Yersinia enterocolitica strains. Appl. Environ. Microbiol. 67:5634-5642.
41. Talbot, G. H., J. Bradley, J. E. Edwards, D. Gilbert, and M. Scheld. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
42. Uratani, Y., and T. Hoshino. 1984. Pyocin R1 inhibits active transport in Pseudomonas aeruginosa and depolarizes membrane potential. J. Bacteriol. 157:632-636.
43. Walterer, G. W., and R. G. Wunderink. 2001. Increasing threat of Gram-negative bacteria. Crit. Care Med. 29:N75-N81.
44. Watanabe, R., T. Matsumoto, G. Sano, Y. Ishii, K. Tateda, Y. Sumiyama, J. Uchiyama, S. Sakurai, S. Matsuzaki, S. Imai, and K. Yamaguchi. 2007. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51:446-452.
45. Woods, J. W., Jr., I. H. Manning, Jr., and C. N. Patterson. 1951. Monilial infections complicating the therapeutic use of antibiotics. JAMA 145:207-211.
46. Zink, R., M. J. Loessner, and S. Schere. 1995. Characterization of cryptic prophages (monocins) in Listeria and sequence analysis of a holin/endolysin gene. Microbiology 141:2577-2584.